
T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer
Ado-trastuzumab emtansine (T-DM1; Kadcyla) in combination with palbociclib (Ibrance) showed signs of efficacy in patients with HER2-positive metastatic breast cancer, according to data from a phase 2 trial (NCT03530696) presented during the 2025 ESMO …